Related Experiment Video

Updated: Mar 14, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
10:49

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus

Published on: January 28, 2019

9.5K

Rotavirus-associated immune thrombocytopenic purpura in children: A retrospective study

Qi Ai1, Jing Yin2, Sen Chen1

  • 1Department of Hematology, Tianjin Children's Hospital, Tianjin 301800, P.R. China.

Experimental and Therapeutic Medicine
|October 5, 2016
PubMed

Insights

Rotavirus infection may cause immune thrombocytopenic purpura (ITP) in children. Children with rotavirus diarrhea had higher ITP incidence and distinct clinical features, suggesting a causative role.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Hematology

Background:

  • Previous studies suggest a link between rotavirus infection and primary immune thrombocytopenic purpura (ITP).
  • The potential causative role of rotavirus in pediatric ITP requires further investigation.

Purpose of the Study:

  • To investigate the causative role of rotavirus infection in the development of ITP in children.
  • To compare the incidence and clinical features of ITP in children with and without rotavirus infection.

Main Methods:

  • Retrospective study design.
  • Comparison of ITP incidence rates in children with and without rotavirus diarrhea.
  • Analysis of clinical features, including age, mean platelet volume (MPV), and bleeding score, in ITP patients with or without rotavirus infection.

Main Results:

  • The incidence of ITP was higher in children with rotavirus diarrhea (14.58%) compared to those without (7.22%).
  • ITP children with rotavirus infection were significantly younger.
  • ITP children with rotavirus infection exhibited decreased mean platelet volume (MPV) and a higher frequency of severe bleeding (bleeding score of 3).

Conclusions:

  • Rotavirus infection is associated with a higher incidence of ITP in children.
  • Rotavirus infection may play a causative role in pediatric ITP.
  • Clinical presentation of rotavirus-associated ITP differs from non-rotavirus ITP, particularly in younger children with lower MPV and increased bleeding severity.

Keywords:
childrenimmune thrombocytopenic purpurarotavirus

More Related Videos

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR15:16

Detection and Genogrouping of Noroviruses from Children's Stools By Taqman One-step RT-PCR

Published on: July 22, 2012

17.9K
Author Spotlight: Investigating Viral Disruption of Intestinal Epithelial Signaling – Research Insights and Future Directions08:01

Author Spotlight: Investigating Viral Disruption of Intestinal Epithelial Signaling – Research Insights and Future Directions

Published on: January 19, 2024

2.0K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
626
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
309
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
414